Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ledipasvir

Catalog No: tcsc1653

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1256388-51-8

Formula:
$C_{49}H_{54}F_2N_8O_6$

Pathway:
Metabolic Enzyme/Protease;Anti-infection

Target:
HCV Protease;HCV

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
GS-5885

Observed Molecular Weight:
889

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Ledipasvir is an inhibitor of the **hepatitis C virus NS5A**, with **EC_{50}** values of 34 pM against GT1a and 4 pM against GT1b replicon.

IC50 & Target: EC50: 34 pM (GT1a), 4 pM (GT1b)[1]

In Vitro: Ledipasvir has GT1a and 1b EC_{50} values of 31 and 4 pM, respectively, and protein-adjusted EC_{50} values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC_{50} of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay[1]. Ledipasvir exhibits an EC_{50} value of 141 nM against the JFH/3a-NS5A replicon[2].

In Vivo: Ledipasvir is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey and low predicted clearance in human. The pharmacokinetics of Ledipasvir is measured in rats and dogs. Ledipasvir shows good half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume[1].